project id: TCGA-PRAD; case submitter id: TCGA-HC-A631; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.86; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.39; rna integrity number: 8.4; age at index: 67; days to birth: -24749; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1945; age at diagnosis: 24749; ajcc clinical m: M0; ajcc clinical t: T2; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 54.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 4; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 5; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: not reported; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 101; days to sample procurement: 0; initial weight: 40.0; portion submitter id: TCGA-HC-A631-01A-11; percent lymphocyte infiltration: 0.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 0.0; percent stromal cells: 35.0; percent tumor cells: 65.0; percent tumor nuclei: 80.0;